A similar result was obtained in 295,907 adults with T2DM, with a lower incidence of gout after initiation of SGLT-2 inhibitor therapy than GLP-1RA therapy (difference rate: 2.9 per 1000 person-years) [95]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.